Literature DB >> 28766723

Comparing transfusion reaction rates for various plasma types: a systematic review and meta-analysis/regression.

Nicholas H Saadah1,2, Fabienne M A van Hout1,2,3, Martin R Schipperus4,5, Saskia le Cessie2, Rutger A Middelburg1,2, Johanna C Wiersum-Osselton5,6, Johanna G van der Bom1,2.   

Abstract

BACKGROUND: We estimated rates for common plasma-associated transfusion reactions and compared reported rates for various plasma types. STUDY DESIGN AND METHODS: We performed a systematic review and meta-analysis of peer-reviewed articles that reported plasma transfusion reaction rates. Random-effects pooled rates were calculated and compared between plasma types. Meta-regression was used to compare various plasma types with regard to their reported plasma transfusion reaction rates.
RESULTS: Forty-eight studies reported transfusion reaction rates for fresh-frozen plasma (FFP; mixed-sex and male-only), amotosalen INTERCEPT FFP, methylene blue-treated FFP, and solvent/detergent-treated pooled plasma. Random-effects pooled average rates for FFP were: allergic reactions, 92/105 units transfused (95% confidence interval [CI], 46-184/105 units transfused); febrile nonhemolytic transfusion reactions (FNHTRs), 12/105 units transfused (95% CI, 7-22/105 units transfused); transfusion-associated circulatory overload (TACO), 6/105 units transfused (95% CI, 1-30/105 units transfused); transfusion-related acute lung injury (TRALI), 1.8/105 units transfused (95% CI, 1.2-2.7/105 units transfused); and anaphylactic reactions, 0.8/105 units transfused (95% CI, 0-45.7/105 units transfused). Risk differences between plasma types were not significant for allergic reactions, TACO, or anaphylactic reactions. Methylene blue-treated FFP led to fewer FNHTRs than FFP (risk difference = -15.3 FNHTRs/105 units transfused; 95% CI, -24.7 to -7.1 reactions/105 units transfused); and male-only FFP led to fewer cases of TRALI than mixed-sex FFP (risk difference = -0.74 TRALI/105 units transfused; 95% CI, -2.42 to -0.42 injuries/105 units transfused).
CONCLUSION: Meta-regression demonstrates that the rate of FNHTRs is lower for methylene blue-treated compared with FFP, and the rate of TRALI is lower for male-only than for mixed-sex FFP; whereas no significant differences are observed between plasma types for allergic reactions, TACO, or anaphylactic reactions. Reported transfusion reaction rates suffer from high heterogeneity.
© 2017 AABB.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28766723     DOI: 10.1111/trf.14245

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  8 in total

1.  Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies.

Authors:  Giustina De Silvestro; Giorgio Gandini; Francesco Fiorin; Piero Marson; Ersilia Barbone; Andrea Frigato; Gianluca Gessoni; Arianna Veronesi; Monia Pacenti; Monica Castelli; Marianna Rinaldi; Monica Rizzi; Francesca Stefani; Giovanni Roveroni
Journal:  Transfus Apher Sci       Date:  2021-05-07       Impact factor: 1.764

2.  Is all plasma created equal? A pilot study of the effect of interdonor variability.

Authors:  Amanda M Chipman; Shibani Pati; Daniel Potter; Feng Wu; Maximillian Lin; Rosemary A Kozar
Journal:  J Trauma Acute Care Surg       Date:  2020-01       Impact factor: 3.697

3.  Safety and tolerability of solvent/detergent-treated plasma for pediatric patients requiring therapeutic plasma exchange: An open-label, multicenter, postmarketing study.

Authors:  Cassandra D Josephson; Stuart Goldstein; David Askenazi; Claudia S Cohn; Philip C Spinella; Ara Metjian; Ross M Fasano; Lejla Music-Aplenc
Journal:  Transfusion       Date:  2021-12-20       Impact factor: 3.337

4.  Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026).

Authors:  Chintamani Atreya; Simone Glynn; Michael Busch; Steve Kleinman; Edward Snyder; Sara Rutter; James AuBuchon; Willy Flegel; David Reeve; Dana Devine; Claudia Cohn; Brian Custer; Raymond Goodrich; Richard J Benjamin; Anna Razatos; Jose Cancelas; Stephen Wagner; Michelle Maclean; Monique Gelderman; Andrew Cap; Paul Ness
Journal:  Transfusion       Date:  2019-05-29       Impact factor: 3.157

Review 5.  Methylene blue-treated plasma, versus quarantine fresh frozen plasma, for acute thrombotic thrombocytopenic purpura treatment: Comparison between centres and critical review on longitudinal data.

Authors:  José Luis Arroyo; Eva Martínez; Cristina Amunárriz; Carmen Muñoz; Iñigo Romón; Ignacio Álvarez; José María García
Journal:  Transfus Apher Sci       Date:  2020-04-12       Impact factor: 1.764

Review 6.  Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic.

Authors:  Nandeeta Samad; Temitayo Eniola Sodunke; Hasan Al Banna; Ashmita Sapkota; Aneeka Nawar Fatema; Katia Iskandar; Dilshad Jahan; Timothy Craig Hardcastle; Tanzina Nusrat; Tajkera Sultana Chowdhury; Mainul Haque
Journal:  Risk Manag Healthc Policy       Date:  2020-11-23

7.  Active surveillance of serious adverse events following transfusion of COVID-19 convalescent plasma.

Authors:  Erica Swenson; Lisa Kanata Wong; Perrin Jhaveri; Yingjie Weng; Shanthi Kappagoda; Suchitra Pandey; Angelica Pritchard; Angela Rogers; Stephen Ruoss; Aruna Subramanian; Hua Shan; Marie Hollenhorst
Journal:  Transfusion       Date:  2021-10-22       Impact factor: 3.337

8.  Incidence of transfusion-related acute lung injury temporally associated with solvent/detergent plasma use in the ICU: A retrospective before and after implementation study.

Authors:  Robert B Klanderman; Nielsvan van Mourik; Dorus Eggermont; Anna-Linda Peters; Pieter R Tuinman; Rob Bosman; Henrik Endeman; Olaf L Cremer; Sesmu M Arbous; Alexander P J Vlaar
Journal:  Transfusion       Date:  2022-08-02       Impact factor: 3.337

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.